RU2385322C2 - Способ заживления ран с применением антагонистов аденозинового рецептора a2b - Google Patents

Способ заживления ран с применением антагонистов аденозинового рецептора a2b Download PDF

Info

Publication number
RU2385322C2
RU2385322C2 RU2007107605/04A RU2007107605A RU2385322C2 RU 2385322 C2 RU2385322 C2 RU 2385322C2 RU 2007107605/04 A RU2007107605/04 A RU 2007107605/04A RU 2007107605 A RU2007107605 A RU 2007107605A RU 2385322 C2 RU2385322 C2 RU 2385322C2
Authority
RU
Russia
Prior art keywords
formula
methyl
compounds
amino
dione
Prior art date
Application number
RU2007107605/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2007107605A (ru
Inventor
Дэвань ЦЗЕН (US)
Дэвань ЦЗЕН
Луис БЕЛАРДИНЕЛЛИ (US)
Луис Белардинелли
Original Assignee
Си Ви Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Си Ви Терапьютикс, Инк. filed Critical Си Ви Терапьютикс, Инк.
Publication of RU2007107605A publication Critical patent/RU2007107605A/ru
Application granted granted Critical
Publication of RU2385322C2 publication Critical patent/RU2385322C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
RU2007107605/04A 2004-09-01 2005-08-30 Способ заживления ран с применением антагонистов аденозинового рецептора a2b RU2385322C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60667504P 2004-09-01 2004-09-01
US60/606,675 2004-09-01

Publications (2)

Publication Number Publication Date
RU2007107605A RU2007107605A (ru) 2008-09-10
RU2385322C2 true RU2385322C2 (ru) 2010-03-27

Family

ID=35695744

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007107605/04A RU2385322C2 (ru) 2004-09-01 2005-08-30 Способ заживления ран с применением антагонистов аденозинового рецептора a2b

Country Status (21)

Country Link
US (1) US20060058322A1 (cg-RX-API-DMAC7.html)
EP (1) EP1789053B1 (cg-RX-API-DMAC7.html)
JP (2) JP4929173B2 (cg-RX-API-DMAC7.html)
KR (1) KR101247528B1 (cg-RX-API-DMAC7.html)
CN (1) CN101043889B (cg-RX-API-DMAC7.html)
AU (1) AU2005282860B2 (cg-RX-API-DMAC7.html)
CA (1) CA2578702A1 (cg-RX-API-DMAC7.html)
DK (1) DK1789053T3 (cg-RX-API-DMAC7.html)
ES (1) ES2387653T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20120712T1 (cg-RX-API-DMAC7.html)
IL (1) IL181634A (cg-RX-API-DMAC7.html)
MX (1) MX2007002437A (cg-RX-API-DMAC7.html)
NO (1) NO20071718L (cg-RX-API-DMAC7.html)
NZ (1) NZ553487A (cg-RX-API-DMAC7.html)
PL (1) PL1789053T3 (cg-RX-API-DMAC7.html)
PT (1) PT1789053E (cg-RX-API-DMAC7.html)
RS (1) RS52455B (cg-RX-API-DMAC7.html)
RU (1) RU2385322C2 (cg-RX-API-DMAC7.html)
SI (1) SI1789053T1 (cg-RX-API-DMAC7.html)
WO (1) WO2006028810A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200701777B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1658291B1 (en) 2003-08-25 2013-10-02 Dogwood Pharmaceuticals, Inc. Substituted 8-heteroaryl xanthines
EP2311462A1 (en) 2004-10-15 2011-04-20 Cv Therapeutics, Inc. Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists
WO2006091897A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Derivatives of 8-substituted xanthines
US7598379B2 (en) * 2005-02-25 2009-10-06 Pgx Health, Llc Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
WO2006091898A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Pyrazolyl substituted xanthines
CA2612344A1 (en) * 2005-06-16 2006-12-28 Cv Therapeutics, Inc. Prodrugs of a2b adenosine receptor antagonists
US7884100B2 (en) 2006-06-16 2011-02-08 Pgxhealth, Llc Substituted 8-[6-amino-3-pyridyl]xanthines
US7767685B2 (en) * 2006-06-29 2010-08-03 King Pharmaceuticals Research And Development, Inc. Adenosine A2B receptor antagonists
JP5460690B2 (ja) * 2008-03-26 2014-04-02 アドヴィナス・セラピューティックス・リミテッド アデノシンレセプターアンタゴニストとしてのヘテロ環化合物
JP7849948B2 (ja) * 2018-03-05 2026-04-22 テオン セラピューティクス,インク. アデノシン受容体アンタゴニストおよびその使用
CN108864114B (zh) * 2018-06-04 2020-11-06 应世生物科技(南京)有限公司 选择性a2a受体拮抗剂
EP4211135A1 (en) * 2020-09-04 2023-07-19 Teon Therapeutics, Inc. Cocrystals of an adenosine a2b receptor antagonist

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932558A (en) * 1993-04-15 1999-08-03 New York University Adenosine receptor agonists for the promotion of wound healing

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452788A (en) * 1982-04-21 1984-06-05 Warner-Lambert Company Substituted 8-phenylxanthines
US4593095A (en) * 1983-02-18 1986-06-03 The Johns Hopkins University Xanthine derivatives
US4558051A (en) * 1983-10-11 1985-12-10 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same
GB8510758D0 (en) * 1985-04-27 1985-06-05 Wellcome Found Compounds
DE3843117A1 (de) * 1988-12-22 1990-06-28 Boehringer Ingelheim Kg Neue xanthinderivate mit adenosin-antagonistischer wirkung
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
US5446046A (en) * 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
GB9415529D0 (en) * 1994-08-01 1994-09-21 Wellcome Found Phenyl xanthine derivatives
DE19535504A1 (de) * 1995-09-25 1997-03-27 Bayer Ag Substituierte Xanthine
GB9703044D0 (en) * 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
US6060481A (en) * 1998-05-28 2000-05-09 The Penn State Research Foundation Method for improving insulin sensitivity using an adenosine receptor antagonist
US6545002B1 (en) * 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
US6894021B2 (en) * 2000-02-17 2005-05-17 Cv Therapeutics, Inc. Method for identifying and using A2B adenosine receptor antagonists to mediate mammalian cell proliferation
US20020065286A1 (en) * 2000-08-21 2002-05-30 Davies Michael John Treatment of wounds
US7490726B2 (en) * 2001-09-06 2009-02-17 Alexander Virvo Soft toy holder
US6437154B1 (en) * 2001-09-28 2002-08-20 Council Of Scientific And Industrial Research Process for the preparation of 10-deacetylbaccatin III
AU2002359365B2 (en) * 2001-11-09 2008-07-10 Gilead Sciences, Inc. A2B adenosine receptor antagonists
US7317017B2 (en) * 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US6977300B2 (en) * 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
JP4051481B2 (ja) * 2002-11-29 2008-02-27 ヤマハマリン株式会社 船外機
EP1636229A4 (en) * 2003-06-06 2008-07-30 Endacea Inc ADENOSINE A1 RECEPTOR ANTAGONISTS
US7449473B2 (en) * 2003-10-31 2008-11-11 Cv Therapeutics, Inc. Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932558A (en) * 1993-04-15 1999-08-03 New York University Adenosine receptor agonists for the promotion of wound healing

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FEOKTISTOV I.; ET AL, PHARMACOLOGICAL REVIEWS, 1997. Vol:49, Nr:4, Page(s): 381-402. Feoktistov I.; Biaggioni I.; Polosa R.; Holgate S. Т., TRENDS IN PHARMACOLOGICAL SCIENCES, 1998, Vol:19, Nr:4, Page(s): 148-153. *
ROHOVSKY S. AND D'AMORE P. A., GROWTH FACTORS WOUND HEALING, 1997, Page(s): 8-26. *

Also Published As

Publication number Publication date
CN101043889A (zh) 2007-09-26
IL181634A (en) 2015-05-31
PL1789053T3 (pl) 2012-12-31
JP2011246492A (ja) 2011-12-08
JP4929173B2 (ja) 2012-05-09
PT1789053E (pt) 2012-08-09
ES2387653T3 (es) 2012-09-27
WO2006028810A3 (en) 2006-09-28
US20060058322A1 (en) 2006-03-16
WO2006028810A2 (en) 2006-03-16
DK1789053T3 (da) 2012-08-06
HK1107261A1 (en) 2008-04-03
CN101043889B (zh) 2010-11-03
NZ553487A (en) 2010-09-30
AU2005282860B2 (en) 2012-03-22
RU2007107605A (ru) 2008-09-10
KR101247528B1 (ko) 2013-04-15
MX2007002437A (es) 2007-08-14
HRP20120712T1 (hr) 2012-10-31
CA2578702A1 (en) 2006-03-16
RS52455B (sr) 2013-02-28
KR20070047816A (ko) 2007-05-07
AU2005282860A1 (en) 2006-03-16
EP1789053B1 (en) 2012-06-13
EP1789053A2 (en) 2007-05-30
ZA200701777B (en) 2008-09-25
NO20071718L (no) 2007-03-30
JP2008511654A (ja) 2008-04-17
IL181634A0 (en) 2007-07-04
SI1789053T1 (sl) 2012-09-28

Similar Documents

Publication Publication Date Title
JP2011246492A (ja) A2bアデノシンレセプターアンタゴニストを使用する創傷治癒の方法
AU2007227021B2 (en) Method of preventing and treating hepatic disease using A2B adenosine receptor antagonists
RU2374247C2 (ru) Способ получения антагонистов аденозиновых рецепторов a2b и промежуточные продукты
AU2005295654B2 (en) Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists
KR20050044361A (ko) A2b 아데노신 수용체 길항제
US7317017B2 (en) A2B adenosine receptor antagonists
US20080318983A1 (en) A2b adenosine receptor antagonists
EP3103454A1 (en) Use of a2b adenosine receptor antagonists for treating heart failure and arrhythmia in post-myocardial infarction patients
HK1107261B (en) Method of wound healing using a2b adenosine receptor antagonists
AU2011202523B2 (en) A2B adenosine receptor antagonists
EA042138B1 (ru) Подкожное введение антагониста p2y12 рецептора

Legal Events

Date Code Title Description
PD4A Correction of name of patent owner
PC41 Official registration of the transfer of exclusive right

Effective date: 20140702